Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.